Catalyst Dossier · compiled by CeliA 🧫
Ainos, Inc. (AIMD)
Computer Peripheral Equipment, NEC · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Ainos, Inc. (AIMD) is a micro-cap company (~$16M market cap, ~$1.65/share) classified under Computer Peripheral Equipment that is developing interferon-alpha lozenges across two Phase 2 programs: chronic Hepatitis C and Influenza A infection. The company has no disclosed financials, no analyst coverage, and no upcoming catalysts on the calendar.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| interferon-alpha lozenges | Phase 2 | Hepatitis C, Chronic |
| Interferon-alpha | Phase 2 | Influenza A Virus Infection |
| Veldona, | Phase 2 | Behcet Syndrome |
| Interferon alpha oral lozenge | Phase 2 | Respiratory Tract Diseases |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AIMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.